Interactive worksheet
Interactive worksheet
Clinical inputs
0/3 filled
Clinical contextWhy this tool matters and how to interpret it
Understand the result,
not just the number.
ICOS Biomarker Model: Explanation and Clinical Context The ICOS Biomarker Model integrates cardiac biomarkers and echocardiographic parameters to assess the risk of cardiotoxicity in cancer patients. Elevated levels of troponin (>16 ng/L) and BNP (>100 pg/mL), along with a reduced global longitudinal strain (<-18%), are indicative of increased risk. This model aids clinicians in early identification and management of patients at high risk for cardiotoxicity.
Evidence & references1 primary source mapped
- Source 1
Meessen JMTA, et al. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. Eur J Heart Fail. 2020;22(5):900-909. doi:10.1002/ehf2.12695
Clinical discussionModerated, tool-specific conversation
Loading discussion…